1613319-05-3

Basic information

• Product Name: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide N-methyl-2-pyrrolidone
• Synonyms: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide N-methyl-2-pyrrolidone
• CAS NO: 1613319-05-3
• Molecular Weight: 587.146
• Mol File: 1613319-05-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide N-methyl-2-pyrrolidone(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide N-methyl-2-pyrrolidone(1613319-05-3)
• EPA Substance Registry System: N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazole carboxamide N-methyl-2-pyrrolidone(1613319-05-3)

Safety Data

• Hazardous Substances Data: 1613319-05-3(Hazardous Substances Data)

Upstream product

• 103-76-4 1-(2-hydroxyethyl)piperazine 
• 872-50-4 1-methyl-pyrrolidin-2-one 
• 302964-08-5 2-(6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide 

Relevant articles and documents

A METHOD FOR THE PREPARATION AND PURIFICATION OF NEW AND KNOWN POLYMORPHS AND SOLVATES OF DASATINIB

A preparation method of anhydrous dasatinib in the polymorph form N-6 of formula (I), characterized by the following reflections in an X-ray powder pattern, measured using the CuKa radiation: 6.8; 12.3; 13.2; 13.8; 16.7; 21.0; 24.3 and 24,8 ± 0,2° 2-theta, said method consisting of the following steps: a) preparation and isolation of dasatinib in the form of a solvate or in unsolvated form; b) dissolution of dasatinib obtained in step a) in a crystallization solvent selected from lower alcohols; c) addition of a co-solvent selected from acetonitrile and propionitrile, or a mixture thereof, and isolation of crystalline dasatinib in the polymorph form N-6.